Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

6,385.00GBp
19 Mar 2019
Change (% chg)

35.00 (+0.55%)
Prev Close
6,350.00
Open
6,332.00
Day's High
6,403.00
Day's Low
6,332.00
Volume
324,155
Avg. Vol
2,124,416
52-wk High
6,432.48
52-wk Low
4,746.00

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.04
Market Cap(Mil.): £65,514.78
Shares Outstanding(Mil.): 1,265.91
Dividend: 68.90
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 22.12 29.30 32.54
EPS (TTM): 2.34 -- --
ROI: 7.86 14.23 13.82
ROE: 28.47 15.46 15.25

BioNTech hires banks for IPO worth up to $800 million: sources

FRANKFURT BioNTech, Europe's largest unlisted biotech firm by staff numbers, has hired banks to prepare for an initial public offering (IPO) worth as much as $800 million as early as this year, people familiar with the plan told Reuters.

12 Mar 2019

BioNTech hires banks for IPO worth up to $800 million - sources

FRANKFURT BioNTech, Europe's largest unlisted biotech firm by staff numbers, has hired banks to prepare for an initial public offering (IPO) worth as much as $800 million (611.3 million pounds) as early as this year, people familiar with the plan told Reuters.

12 Mar 2019

UPDATE 2-BioNTech hires banks for IPO worth up to $800 million -sources

* IPO eyed in Q4 or early 2020-sources (Adds BioNTech comment)

12 Mar 2019

AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study

British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for a rare type of pancreatic cancer.

26 Feb 2019

AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study

British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for a rare type of pancreatic cancer.

26 Feb 2019

UPDATE 1-AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study

Feb 26 British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for a rare type of pancreatic cancer.

26 Feb 2019

AstraZeneca's Lynparza meets main goal of late-stage cancer study

Feb 26 British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for pancreatic cancer.

26 Feb 2019

UPDATE 2-FTSE 100 squeezes out gains; ConvaTec drags midcaps

* ConvaTec slumps on mid-caps (Adds company news items, updates to closing prices)

14 Feb 2019

European shares give up three-month highs after shock U.S. data

LONDON European shares gave up three-month highs on Thursday after a surprise sharp decline in U.S. retail sales pulled stocks lower in afternoon trading, spoiling an initially upbeat session that saw blue-chips such as Nestle shine on strong earnings.

14 Feb 2019

European shares give up three-month highs after shock U.S. data

LONDON European shares gave up three-month highs on Thursday after a surprise sharp decline in U.S. retail sales pulled stocks lower in afternoon trading, spoiling an initially upbeat session that saw blue-chips such as Nestle shine on strong earnings.

14 Feb 2019

Earnings vs. Estimates